Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCAM-1+MSC Injection
- Development stage
- Unknown
- Lead developer
- Health & Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular, Intravenous
01
Overview
VCAM-1+MSC Injection (also known as CD106+MSC) is an off-the-shelf, perinatal tissue-derived mesenchymal stem cell (MSC) therapy being developed by H&B France (Health-Biotech JISHI). The therapy consists of MSCs selected for or overexpressing vascular cell adhesion molecule-1 (VCAM-1/CD106), a cell surface protein that plays a critical role in cell-cell adhesion, homing, and immunosuppression. By utilizing VCAM-1-expressing MSCs, the therapy aims to enhance therapeutic potency, vascular regeneration, and anti-inflammatory effects. VCAM-1+MSC Injection is currently in Phase 1/2 clinical development for the treatment of critical limb ischemia and ischemic stroke.
- Other names
- CD106+MSCCD106+MSC InjectionVCAM-1+MSCVCAM-1+MSC Injection
02
Targets
ICAM1 (Intercellular Adhesion Molecule 1)α4β1 (Integrin α4β1)VCAM1 (Vascular cell adhesion molecule 1)
Beyond the preview
Go deeper on VCAM-1+MSC Injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCAM-1+MSC Injection.